Home » Quality Assurance Control » Wyeth’s Shedlawski Assumes APICS Leadership
Wyeth’s Shedlawski Assumes APICS Leadership
PharmaManufacturing.com
01/09/2007
APICS, The Association for Operations Management, announced Jan. 2 that Joseph F. Shedlawski, CPIM, Principal, Commercial Operations at Wyeth Consumer Healthcare, has been elected as president of its board of directors.
In his current position at Wyeth, Shedlawski is responsible for policies, practices, and metrics to improve and to sustain the cost effectiveness and customer service level of supply management activities. He has more than 25 years of leadership experience in many aspects of operations management, in both plant and headquarters environments, in the pharmaceuticals, vaccines, and consumer products businesses. He holds a Bachelor of Science degree in Biology from Bucknell University and an MBA in Finance with Honors from Iona College.
Shedlawski has been an APICS-Northern New Jersey Chapter member for more than 21 years, and served as that Chapter’s president in 1991. He is an APICS-certified CPIM Instructor as well as Train-the-Trainer Instructor, and has conducted many seminars and presentations for APICS at the Chapter, Regional, and International Conference levels.
“As APICS prepares to celebrate 50 years of service in the operations management profession, I am honored to be leading such a dynamic organization,” said Shedlawski. “I am looking forward to working with the new board to build upon the momentum generated in 2006. In the coming year, APICS will focus on delivering value to individual members and enterprises alike through enhancing products and services, providing the best and most widely recognized certifications in the field, and expanding APICS’ global leadership role in the operations management profession.”
More News:
- 03/18/2010 Teva Beats Out Pfizer & Activa in 3.5BN Rationpharm Generics DealFrom CTV.ca
- 03/18/2010 Johnson & Johnson CEO Weldon Gets 11% 2009 Raise, to $25.6MFrom AP.com
- 03/17/2010 $75 Million Drug Heist is Bitter Pill for LillyFrom IndyStar.com
- 03/17/2010 R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
- 03/15/2010 Diabetes Drug From Lilly, Amylin Under ScrutinyFrom Forbes.com
- 03/12/2010 AstraZeneca Inks First Generic Drugs DealFrom Business.timesonline.co.uk
- 03/12/2010 AstraZeneca Job Cuts Reflect New Landscape For Drug InnovationFrom FT.com
- 03/10/2010 Novartis Goes Wireless for Process and Plant Info
- 03/10/2010 Concerns Raised about Tromethamine ContaminationFrom Rx-360
- 03/09/2010 Pittcon 2010: Thermo Fisher Scientific Continues in Growth Mode
- All news »
Get Connected Now!
- Featured White Papers

Print page